vimarsana.com

தனிப்பட்ட நோயாளி விரிவாக்கப்பட்டது நுழைவு ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

TLSA: Nasally-administered Foralumab Trial in SPMS Patient

By John Vandermosten, CFA NASDAQ:TLSA | LSE:TILS READ THE FULL TLSA RESEARCH REPORT On May 25, 2021, Tiziana Life Sciences PLC (NASDAQ:TLSA ) (LSE:TILS) announced that it had initiated a trial through the Individual Patient Expanded Access Program (EAP) of foralumab in a Secondary Progressive Multiple Sclerosis (SPMS) patient. This follows a previous release in late March that first introduced the effort that was cleared under the EAP. The first.

First SPMS Patient Dosed With Nasal Spray Antibody Foralumab

First SPMS Patient Dosed With Nasal Spray Antibody Foralumab
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

MS News That Caught My Eye: Nasal Spray Treatment, Anxiety Management, POMS, PoNS

(0) How great is this? As someone who gave himself an injection in his thigh for many years and received IV infusions for many more, an MS antibody treatment sprayed into the nose is wonderful news. T his approval only applies to one patient, however. A Phase 1 clinical trial is underway, and a Phase 2 is expected to begin later this year. I hope this nasal spray, which initially was intended to be an oral medication, proves to be safe and effective. For a first time, an immune-modulating antibody will be given via nasal administration to treat a person with secondary progressive multiple sclerosis (SPMS).

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.